REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB).
David A. Reardon
Research Funding - Celldex
James J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Celldex
Annick Desjardins
No relevant relationships to disclose
Ronald G. Steis
Research Funding - Celldex
Erin M. Dunbar
Honoraria - FLA Hosp
Research Funding - Celldex
Nitin B. Chandramouli
Research Funding - Celldex
Olivier Rixe
Research Funding - Celgene
Jennifer A Green
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
Thomas A. Davis
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
John Howard Sampson
Consultant or Advisory Role - Celldex
Stock Ownership - Celldex
Honoraria - Celldex
Research Funding - Celldex